Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945935 | 0.89 | — | — | |
| SCHEMBL29953586 | 0.83 | FFAR4 (0.36) | IRAK4ALDH1A1FFAR4 | |
| SCHEMBL1064844 | 0.83 | FFAR4 (0.36) | IRAK4ALDH1A1FFAR4 | |
| SCHEMBL16687411 | 0.77 | TRPV3 (0.35) | IRAK4ALDH1A1LMNAPOLBMAPT | |
| SCHEMBL20361724 | 0.75 | IRAK4 (0.33) | IRAK4ALDH1A1MAPTFFAR4 | |
| SCHEMBL16687409 | 0.74 | HPGD (0.39) | ALDH1A1LMNAPOLBMAPTHTT | |
| SCHEMBL18686415 | 0.74 | CSNK2A1 (0.31) | — | |
| SCHEMBL13429952 | 0.74 | CSNK2A1 (0.31) | — | |
| SCHEMBL16687387 | 0.73 | CA1 (0.33) | — | |
| SCHEMBL26769952 | 0.73 | CSNK2A1 (0.39) | IRAK4ALDH1A1MAPTFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2015-11-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9024071-B2 | Therapeutic compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | IRAK4 1865/4885ALDH1A1 4010/4885LMNA 3453/4885 |
| US-20150315127-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | IRAK4 1865/4885ALDH1A1 4010/4885LMNA 3453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.